The PCAC review happened July 23–24, 2026. Here is what that means for peptide access.

For the first time, the legitimate version of the peptide market got decided in public. On July 23 and 24, 2026, an advisory committee at the FDA’s White Oak campus in Silver Spring reviewed seven peptides and recommended which of them a US pharmacy may eventually be allowed to make you by prescription.

That’s the good news, and it’s real. The catch is in the detail: the committee voted on specific indications, most of them nothing like what the off-label market sells these for. If you’re tracking one of these seven, the exact wording of what was on the docket matters more than the fact that it was on the docket at all. (What the PCAC is and what its vote does is the mechanics; this is the line-up.)

July 23 — four compounds

The docket itself comes from the April 2026 Federal Register notice 2026-07361; the FDA-reviewed indications below come off the agency’s advisory-committee calendar page for the meeting. Keep one eye on the gap between each indication and the way the compound is actually marketed.

BPC-157 — reviewed for ulcerative colitis. The peptide the injury forums built a whole stack around went in front of the committee for a gut condition, leaning on its mucosal-protection research, not the tendon-and-joint use every vendor sells it for. On July 23, 2026, the committee recommended BPC-157 for inclusion on the 503A Bulk Drug Substances List; FDA final action is pending.

KPV — for wound healing and inflammatory conditions. A tripeptide fragment of alpha-melanocyte-stimulating hormone; the dual indication tracks its dual mechanism, skin repair on one side, anti-inflammatory action on the other. Legal-trade coverage of the July 23, 2026 session reports KPV recommended alongside BPC-157, but FDA’s own per-substance tally sheet hasn’t posted, so treat that as reported, not confirmed.

TB-500 — for wound healing. The thymosin-beta-4-derived peptide that anchors the other half of the injury stack, and the docketed use is narrower than the marketing. TB-500 got its own separate ballot on July 23, 2026 and was also recommended for inclusion on the 503A Bulk Drug Substances List; FDA final action is pending on that one too.

MOTs-C — for obesity and osteoporosis. This is the sharpest case of indication drift on the whole docket. MOTs-C sells across the longevity market as a mitochondrial anti-ageing peptide. The committee reviewed it on July 23, 2026 for body composition and bone density instead. Different drug, on paper. No outcome for MOTs-C has been made public.

July 24 — three more

Emideltide (DSIP) — for opioid withdrawal, chronic insomnia, and narcolepsy. Emideltide is the registered name; the compound is the one most literature still calls delta sleep-inducing peptide. Three indications, all neurological, and the committee heard them on July 24, 2026. No outcome for Emideltide has been made public.

Semax — for cerebral ischemia, migraine, and trigeminal neuralgia. A short heptapeptide developed in Russia in the 1980s for stroke recovery. Whatever the forums claim about cognitive enhancement wasn’t the question in front of the committee on July 24, 2026. No outcome for Semax has been made public.

Epitalon — for insomnia. The longevity market sells this one as a telomere compound. The committee reviewed it on July 24, 2026 for sleep. Marketing and record, looking at different things again. No outcome for Epitalon has been made public.

Hold onto the pattern. In every case but TB-500, the indication the committee voted on is narrower or plain different from the one the supplement market pushes. A recommendation attaches to the indication on the record, and the off-label uses most buyers actually care about sit outside it.

The five queued for February 2027

The same April 2026 action scheduled a second meeting before the end of February 2027 for five more: Dihexa acetate, LL-37, GHK-Cu, PEG-MGF, and Melanotan II. The exact date isn’t published yet.

GHK-Cu is the one worth a careful line, because it shows how much the route of administration writes the story. The FDA split it in two, and the two routes moved in opposite directions. Injectable GHK-Cu — the form sold in vials off-label — came off Category 2, the do not compound list. Topical GHK-Cu was pulled off Category 1, the under evaluation list that had let compounders make it under enforcement discretion, so the cream lost a safe harbor it used to have. Both go to February; the live question is the injection. Anyone waving vaguely toward GHK-Cu and PCAC without saying which route and which direction is compressing the one detail that matters.

The peptides that already lost

Here’s the part most forum coverage gets wrong. Several compounds the market still files under PCAC peptides aren’t on the July docket, aren’t on the February docket, and aren’t awaiting review. They already had their hearing, in 2024, and the committee voted against them.

Ipamorelin went to the October 29, 2024 meeting. CJC-1295, AOD-9604, and Thymosin alpha-1 went to the December 4, 2024 meeting. All four: voted against inclusion on the 503A list. The FDA’s reasoning ran to a consistent triplet — insufficient human safety data, mechanistic concerns about unintended endocrine effects, and a lack of reproducible efficacy outside small or open-label trials. (Thymosin alpha-1 carried an extra wrinkle: it sits under biologics regulation, not the small-molecule 503A framework most peptides ride.) None of the four is getting another shot in 2026 or 2027. Not on the upcoming dockets is technically true and quietly misleading — the honest version is heard already, and lost. The fuller story of that vote is its own piece.

A separate set sits outside the PCAC question for structural reasons rather than a lost vote: sermorelin runs under an existing compounding framework after the 2009 Geref withdrawals, selank was never scheduled or voted on, tesamorelin is already an approved drug (Egrifta WR) so it can’t be on a docket for unapproved substances, and PT-141 has its own approval path as Vyleesi. Different lane, not a rejection.

What the two days actually showed

Three things are worth holding onto, looking back at the two days.

First, whether the committee’s discussion held to the FDA-reviewed indication or drifted toward the off-label uses driving demand. It held. Whichever indication a recommendation attaches to is the one a future prescription will have to match.

Second, the safety record FDA staff put on the table. For most of these the human evidence was thin enough to fit on one chart. How thin the staff called it matters more than the marketing volume around any single compound.

Third, the vote splits. PCAC records votes by member, and on the two named ballots, BPC-157 and TB-500, the splits came in close: 8-6 with one abstention on each, per legal-trade coverage. A unanimous no and a narrow 8-6 yes mean very different things for the rulemaking that follows, even when a summary flattens both into a verdict.

And then the wait. A recommendation on July 23 and 24, 2026 isn’t a prescription today. The rulemaking that turns a recommendation into access runs months at minimum. The meeting set direction. The rule sets the date.

Where the seven stand now

Right now the only supply chain for all twelve peptides across both PCAC waves runs through research-chemical sites, vials labelled not for human consumption, no testing, no prescription, no physician. July 23 and 24 were the first formal gate between that and a real one: a doctor’s script, a licensed pharmacy, a named indication, an assay on the batch.

BPC-157 and TB-500 cleared that gate with a recommendation. What FDA decides on both, and on the rest of the July slate, is what’s still genuinely open, along with the day the supervised route actually opens. Building the operation that dispenses them the moment that happens, supervised, licensed, tested, is the whole point of Wolverine Health. Leave your email and we’ll tell you the moment the one you’re tracking is real.